Skip to main content
Top
Published in: World Journal of Surgery 9/2011

01-09-2011

Pancreatic Cancer: The Challenge of the Future in Tumorigenesis-based Prevention

Authors: Ernst Hanisch, Charalabos Batsis

Published in: World Journal of Surgery | Issue 9/2011

Login to get access

Excerpt

Pancreatic cancer represents one of the greatest challenges of biomedical science. In a recent issue of the World Journal of Surgery, Dr. Fisher [1] objectively describes the limitations of current screening and therapeutic approaches in the management of this highly fatal disease. With a 97-98% 5-year mortality rate, pancreatic cancer has the poorest prognosis among nearly all cancer types. The 5-year survival rate of ~20%, compared with over 90% for other common cancer types such as breast, colorectal, or stomach for localized disease according to recent US cancer statistics [2], reflects the high-level of aggressiveness of this disease. …
Literature
1.
2.
3.
go back to reference Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801–1806PubMedCrossRef Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897):1801–1806PubMedCrossRef
4.
go back to reference Yachida S, Jones S, Bozic I et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117PubMedCrossRef Yachida S, Jones S, Bozic I et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117PubMedCrossRef
5.
go back to reference Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef
6.
go back to reference Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef
7.
go back to reference Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRef Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRef
8.
go back to reference Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681PubMedCrossRef Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681PubMedCrossRef
9.
go back to reference Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726PubMedCrossRef Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726PubMedCrossRef
10.
go back to reference Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043PubMedCrossRef Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043PubMedCrossRef
11.
go back to reference Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586PubMedCrossRef Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586PubMedCrossRef
12.
go back to reference Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350CrossRef Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350CrossRef
13.
go back to reference Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef
14.
go back to reference Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRef Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRef
Metadata
Title
Pancreatic Cancer: The Challenge of the Future in Tumorigenesis-based Prevention
Authors
Ernst Hanisch
Charalabos Batsis
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 9/2011
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-011-1058-y

Other articles of this Issue 9/2011

World Journal of Surgery 9/2011 Go to the issue